Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Archives of Gynecology and Obstetrics
Erschienen in: Archives of Gynecology and Obstetrics 5/2024

05.03.2024 | Review

Periostin’s role in uterine leiomyoma development: a mini-review on the potential periostin poses as a pharmacological intervention for uterine leiomyoma

verfasst von: Zahra G. Kiesler, Mark I. Hunter, Ahmed Z. Balboula, Amanda L. Patterson

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Uterine leiomyomas, also known as fibroids or myomas, occur in an estimated 70–80% of reproductive aged women. Many experience debilitating symptoms including pelvic pain, abnormal uterine bleeding (AUB), dyspareunia, dysmenorrhea, and infertility. Current treatment options are limited in preserving fertility, with many opting for sterilizing hysterectomy as a form of treatment. Currently, surgical interventions include hysterectomy, myomectomy, and uterine artery embolization in addition to endometrial ablation to control AUB. Non-surgical hormonal interventions, including GnRH agonists, are connotated with negative side effects and are unacceptable for women desiring fertility. Periostin, a regulatory extra cellular matrix (ECM) protein, has been found to be expressed in various gynecological diseases including leiomyomas. We previously determined that periostin over-expression in immortalized myometrial cells led to the development of a leiomyoma-like cellular phenotype. Periostin is induced by TGF-β, signals through the PI3K/AKT pathway, induces collagen production, and mediates wound repair and fibrosis, all of which are implicated in leiomyoma pathology. Periostin has been linked to other gynecological diseases including ovarian cancer and endometriosis and is being investigated as pharmacological target for treating ovarian cancer, post-surgical scarring, and numerous other fibrotic conditions. In this review, we provide discussion linking pathological inflammation and wound repair, with a TGF-β-periostin-collagen signaling in the pathogenesis of leiomyomas, and ultimately the potential of periostin as a druggable target to treat leiomyomas.
Literatur
1.
Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM (2003) High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188:100–107PubMedCrossRef
2.
Giuliani E, As-Sanie S, Marsh EE (2020) Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet 149:3–9PubMedCrossRef
3.
Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH (2012) The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 206(211):e1-9
4.
Ghant MS, Sengoba KS, Recht H, Cameron KA, Lawson AK, Marsh EE (2015) Beyond the physical: a qualitative assessment of the burden of symptomatic uterine fibroids on women’s emotional and psychosocial health. J Psychosom Res 78:499–503PubMedCrossRef
5.
6.
Islam MS, Ciavattini A, Petraglia F, Castellucci M, Ciarmela P (2018) Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Hum Reprod Update 24:59–85PubMedCrossRef
7.
Malik M, Norian J, Mccarthy-Keith D, Britten J, Catherino WH (2010) Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin Reprod Med 28:169–179PubMedCrossRef
8.
Goad J, Rudolph J, Zandigohar M, Tae M, Dai Y, Wei JJ, Bulun SE, Chakravarti D, Rajkovic A (2022) Single-cell sequencing reveals novel cellular heterogeneity in uterine leiomyomas. Hum Reprod 37:2334–2349PubMedPubMedCentralCrossRef
9.
Protic O, Toti P, Islam MS, Occhini R, Giannubilo SR, Catherino WH, Cinti S, Petraglia F, Ciavattini A, Castellucci M, Hinz B, Ciarmela P (2016) Possible involvement of inflammatory/reparative processes in the development of uterine fibroids. Cell Tissue Res 364:415–427PubMedCrossRef
10.
Ciavattini A, Di Giuseppe J, Stortoni P, Montik N, Giannubilo SR, Litta P, Islam MS, Tranquilli AL, Reis FM, Ciarmela P (2013) Uterine fibroids: pathogenesis and interactions with endometrium and endomyometrial junction. Obstet Gynecol Int 2013:173184PubMedPubMedCentralCrossRef
11.
Munro MG, Critchley HOD, Fraser IS, Committee FMD (2018) The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet 143:393–408PubMedCrossRef
12.
Peddada SD, Laughlin SK, Miner K, Guyon JP, Haneke K, Vahdat HL, Semelka RC, Kowalik A, Armao D, Davis B, Baird DD (2008) Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci U S A 105:19887–19892PubMedPubMedCentralCrossRef
13.
Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R (2017) Epidemiology of uterine fibroids: a systematic review. BJOG 124:1501–1512PubMedCrossRef
14.
Zepiridis LI, Grimbizis GF, Tarlatzis BC (2016) Infertility and uterine fibroids. Best Pract Res Clin Obstet Gynaecol 34:66–73PubMedCrossRef
15.
Makinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M, Aavikko M, Katainen R, Virolainen E, Bohling T, Koski TA, Launonen V, Sjoberg J, Taipale J, Vahteristo P, Aaltonen LA (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334:252–255PubMedCrossRef
16.
Heinonen HR, Sarvilinna NS, Sjoberg J, Kampjarvi K, Pitkanen E, Vahteristo P, Makinen N, Aaltonen LA (2014) MED12 mutation frequency in unselected sporadic uterine leiomyomas. Fertil Steril 102:1137–1142PubMedCrossRef
17.
Mittal P, Shin YH, Yatsenko SA, Castro CA, Surti U, Rajkovic A (2015) Med12 gain-of-function mutation causes leiomyomas and genomic instability. J Clin Invest 125:3280–3284PubMedPubMedCentralCrossRef
18.
Mehine M, Makinen N, Heinonen HR, Aaltonen LA, Vahteristo P (2014) Genomics of uterine leiomyomas: insights from high-throughput sequencing. Fertil Steril 102:621–629PubMedCrossRef
19.
Mehine M, Kaasinen E, Makinen N, Katainen R, Kampjarvi K, Pitkanen E, Heinonen HR, Butzow R, Kilpivaara O, Kuosmanen A, Ristolainen H, Gentile M, Sjoberg J, Vahteristo P, Aaltonen LA (2013) Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med 369:43–53PubMedCrossRef
20.
Wolanska M, Sobolewski K, Drozdzewicz M, Bankowski E (1998) Extracellular matrix components in uterine leiomyoma and their alteration during the tumour growth. Mol Cell Biochem 189:145–152PubMedCrossRef
21.
Stewart EA, Friedman AJ, Peck K, Nowak RA (1994) Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab 79:900–906PubMed
22.
Iwahashi M, Muragaki Y (2011) Increased type I and V collagen expression in uterine leiomyomas during the menstrual cycle. Fertil Steril 95:2137–2139PubMedCrossRef
23.
Iwahashi M, Muragaki Y, Ikoma M, Mabuchi Y, Kobayashi A, Tanizaki Y, Ino K (2011) Immunohistochemical analysis of collagen expression in uterine leiomyomata during the menstrual cycle. Exp Ther Med 2:287–290PubMedPubMedCentralCrossRef
24.
Pickering JG (2001) Regulation of vascular cell behavior by collagen : form is function. Circ Res 88:458–459PubMedCrossRef
25.
26.
Pohlers D, Brenmoehl J, Loffler I, Muller CK, Leipner C, Schultze-Mosgau S, Stallmach A, Kinne RW, Wolf G (2009) TGF-beta and fibrosis in different organs—molecular pathway imprints. Biochim Biophys Acta 1792:746–756PubMedCrossRef
27.
Lee BS, Nowak RA (2001) Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab 86:913–920PubMed
28.
29.
Joseph DS, Malik M, Nurudeen S, Catherino WH (2010) Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. Fertil Steril 93:1500–1508PubMedCrossRef
30.
Chegini N (2010) Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med 28:180–203PubMedPubMedCentralCrossRef
31.
32.
Kim JJ, Sefton EC (2012) The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol 358:223–231PubMedCrossRef
33.
Takeshita S, Kikuno R, Tezuka K, Amann E (1993) Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 294(Pt 1):271–278PubMedPubMedCentralCrossRef
34.
Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF, Kudo A (1999) Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res 14:1239–1249PubMedCrossRef
35.
Wang Z, An J, Zhu D, Chen H, Lin A, Kang J, Liu W, Kang X (2022) Periostin: an emerging activator of multiple signaling pathways. J Cell Commun Signal 16:515–530PubMedPubMedCentralCrossRef
36.
Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, Arron JR, Holweg CTJ, Kudo A (2014) The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci 71:1279–1288PubMedCrossRef
37.
Gonzalez-Gonzalez L, Alonso J (2018) Periostin: a matricellular protein with multiple functions in cancer development and progression. Front Oncol 8:225PubMedPubMedCentralCrossRef
38.
39.
40.
41.
Kobierzycki C, Latkowski KJ, Dziegiel P (2020) The usefulness of periostin determination in gynecology and obstetrics. Ginekol Pol 91:364–351PubMedCrossRef
42.
Yue H, Li W, Chen R, Wang J, Lu X, Li J (2021) Stromal POSTN induced by TGF-beta1 facilitates the migration and invasion of ovarian cancer. Gynecol Oncol 160:530–538PubMedCrossRef
43.
Han X, Wang Q, Wang Y, Hu B, Dong X, Zhang H, Wang W (2019) Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1/microRNA-202-3p/periostin axis modulates invasion and epithelial-mesenchymal transition in human cervical cancer. J Cell Physiol 234:14170–14180PubMedCrossRef
44.
Shen L, Liu P, Zhang P, Zhang X, Cui J (2012) Characterization of periostin expression in human endometrium and endometriotic lesions. Gynecol Endocrinol 28:815–818PubMedCrossRef
45.
Xu X, Zheng Q, Zhang Z, Zhang X, Liu R, Liu P (2015) Periostin enhances migration, invasion, and adhesion of human endometrial stromal cells through integrin-linked kinase 1/akt signaling pathway. Reprod Sci 22:1098–1106PubMedCrossRef
46.
Zheng QM, Lu JJ, Zhao J, Wei X, Wang L, Liu PS (2016) Periostin facilitates the epithelial-mesenchymal transition of endometrial epithelial cells through ILK-Akt signaling pathway. Biomed Res Int 2016:9842619PubMedPubMedCentralCrossRef
47.
Jamaluddin MFB, Ko YA, Kumar M, Brown Y, Bajwa P, Nagendra PB, Skerrett-Byrne DA, Hondermarck H, Baker MA, Dun MD, Scott RJ, Nahar P, Tanwar PS (2018) Proteomic profiling of human uterine fibroids reveals upregulation of the extracellular matrix protein periostin. Endocrinology 159:1106–1118PubMedCrossRef
48.
Lenis YY, George JW, Lind S, Balboula A, Teixeira JM, Patterson AL (2023) The effects of periostin expression on fibroid-like transition of myometrial cells. Reprod Sci 30:1616–1624PubMedCrossRef
49.
Zheng LH, Cai FF, Ge I, Biskup E, Cheng ZP (2014) Stromal fibroblast activation and their potential association with uterine fibroids (Review). Oncol Lett 8:479–486PubMedPubMedCentralCrossRef
50.
51.
Kovacs KA, Lengyel F, Vertes Z, Kornyei JL, Gocze PM, Sumegi B, Szabo I, Vertes M (2007) Phosphorylation of PTEN (phosphatase and tensin homologue deleted on chromosome ten) protein is enhanced in human fibromyomatous uteri. J Steroid Biochem Mol Biol 103:196–199PubMedCrossRef
52.
Karra L, Shushan A, Ben-Meir A, Rojansky N, Klein BY, Shveiky D, Levitzki R, Ben-Bassat H (2010) Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology. Fertil Steril 93:2646–2651PubMedCrossRef
53.
Kim JJ, Kurita T, Bulun SE (2013) Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 34:130–162PubMedPubMedCentralCrossRef
54.
Bulun SE, Moravek MB, Yin P, Ono M, Coon JST, Dyson MT, Navarro A, Marsh EE, Zhao H, Maruyama T, Chakravarti D, Kim JJ, Wei JJ (2015) Uterine leiomyoma stem cells: linking progesterone to growth. Semin Reprod Med 33:357–365PubMedCrossRef
55.
Carrino DA, Mesiano S, Barker NM, Hurd WW, Caplan AI (2012) Proteoglycans of uterine fibroids and keloid scars: similarity in their proteoglycan composition. Biochem J 443:361–368PubMedCrossRef
56.
Yin SL, Qin ZL, Yang X (2020) Role of periostin in skin wound healing and pathologic scar formation. Chin Med J (Engl) 133:2236–2238PubMedCrossRef
57.
Kisseleva T, Brenner DA (2008) Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 233:109–122PubMedCrossRef
58.
American College of Obstetricians and Gynecologists (2008) ACOG practice bulletin. alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol 112:387–400CrossRef
59.
60.
De Bruijn AM, Ankum WM, Reekers JA, Birnie E, Van Der Kooij SM, Volkers NA, Hehenkamp WJ (2016) Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10 year outcomes from the randomized EMMY trial. Am J Obstet Gynecol 215:745–745CrossRef
61.
Kotani Y, Tobiume T, Fujishima R, Shigeta M, Takaya H, Nakai H, Suzuki A, Tsuji I, Mandai M, Matsumura N (2018) Recurrence of uterine myoma after myomectomy: open myomectomy versus laparoscopic myomectomy. J Obstet Gynaecol Res 44:298–302PubMedCrossRef
62.
63.
Hamilton DW (2008) Functional role of periostin in development and wound repair: implications for connective tissue disease. J Cell Commun Signal 2:9–17PubMedPubMedCentralCrossRef
64.
Liu AY, Zheng H, Ouyang G (2014) Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol 37:150–156PubMedCrossRef
65.
Zhu M, Saxton RE, Ramos L, Chang DD, Karlan BY, Gasson JC, Slamon DJ (2011) Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis. Mol Cancer Ther 10:1500–1508PubMedCrossRef
66.
Tai IT, Dai M, Chen LB (2005) Periostin induction in tumor cell line explants and inhibition of in vitro cell growth by anti-periostin antibodies. Carcinogenesis 26:908–915PubMedCrossRef
67.
Yokota K, Kobayakawa K, Saito T, Hara M, Kijima K, Ohkawa Y, Harada A, Okazaki K, Ishihara K, Yoshida S, Kudo A, Iwamoto Y, Okada S (2017) Periostin promotes scar formation through the interaction between pericytes and infiltrating monocytes/macrophages after spinal cord injury. Am J Pathol 187:639–653PubMedCrossRef
Metadaten
Titel
Periostin’s role in uterine leiomyoma development: a mini-review on the potential periostin poses as a pharmacological intervention for uterine leiomyoma
verfasst von
Zahra G. Kiesler
Mark I. Hunter
Ahmed Z. Balboula
Amanda L. Patterson
Publikationsdatum
05.03.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2024
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-024-07435-z

Weitere Artikel der Ausgabe 5/2024

Archives of Gynecology and Obstetrics 5/2024 Zur Ausgabe

Gynecologic Endocrinology and Reproductive Medicine

Reproductive outcomes in women opting for fertility preservation after fertility-sparing surgery for borderline ovarian tumors

General Gynecology

Genome-wide association study (GWAS) identified PCOS susceptibility variants and replicates reported risk variants

General Gynecology

Evaluation of a scoring system to predict treatment success with single-dose methotrexate in ectopic pregnancy

Maternal-Fetal Medicine

Winter, spring, summer or fall: temporal patterns in placenta-mediated pregnancy complications—an exploratory analysis

Urogynecology

The effect of advanced age on peri- and post-operative complications following pelvic floor repair surgeries

Urogynecology

The effect of transobturator tape surgery on female sexual function: a systematic review and meta-analysis

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise